Company Overview and News
Even a sprawling technology player like Microsoft might have trouble going after newly public cybersecurity company Okta's business, CEO Todd McKinnon told CNBC on Thursday.
FireEye Inc.: "FireEye is good. I mean, let's go over the pecking order. I think that Proofpoint is better. I think that Palo Alto Networks – how about that huge insider buy by [new CEO] Nikesh Arora? And then, I have to tell you, I like Nice more, I like Foritnet more, I like Cyberark more and then I will endorse FireEye."
UA FEYE NVCR UAA CGNX PANW WTW ROK
LAS VEGAS, June 19, 2018 (GLOBE NEWSWIRE) -- Aruba, a Hewlett Packard Enterprise company (NYSE:HPE), today announced its Software-Defined Branch (SD-Branch) solution, a new approach designed to help customers modernize branch networks for evolving cloud, IoT and mobility requirements. The integration of new cloud-managed SD-WAN, wired and wireless networking solutions, secured with context-based policy enforcement, significantly advances IT professionals’ ability to deliver improved network availability and application performance, while dramatically reducing management time and operational and capital expenditures.
PANW CHKP HPE
Insider buying increased significantly last week with insiders purchasing $125.17 million of stock compared to $59.2 million in the week prior. Selling also increased with insiders selling $2.24 billion of stock last week compared to $1.61 million in the week prior.
TWTR TWX PANW TWC WMT
Unless you’ve been living under a rock, you know that the narrative surrounding broad markets — it’s been one of strife since late January until the recent rally. Volatility spiked and the S&P 500 Index still sits almost 3% below late-January highs.
LRCX TEVA GS.PRB GS.PRA CDNS DLTR GLSSP FEYE AMZN ALXN AMAT CELG AVGO EBAY SNAP JBK QQQ TTWO TFG VRX CHKP CA CTSH MAR GS.PRJ GS.PRI BABA EXPE ORBK GOOGL GS.PRD GS.PRC QCOM GS.PRN GS.PRK JD XLNX FB ULTA ADP MNST TEVVF PYPL NFLX AMD NVDA GOOG KLAC ATVI MAR.WI GS MYL AAPL KO PAYX IBM EA CELGZ GSC GS.PRICL PANW GSJ BKNG ADPVV TEVJF MU DG MNK BRCM GJS
Since the beginning of 2018, shares of Palo Alto Networks, Inc. (PANW - Free Report) have been on an upswing, appreciating 48.7% in the year so far. The stock crafted a 52-week high of $217.40 during yesterday’s trading session. Over the past year, it has rallied 63.8%, significantly outperforming its industry’s gain of 32.3%. A successful portfolio manager understands the importance of adding well-performing stocks at the right time.
SPG.PRJ GOOGL PANW SPG VMW
Shares of cloud-based security company Palo Alto Networks Inc. (NASDAQ:PANW) rallied 4.4% on Tuesday and in so doing accomplished an important technical feat that now sets up a bullish trade with a well-defined reward to risk for traders and active investors alike.
The cyber-security industry has been putting up an impressive show on the bourse, of late, with the slew of cyber attacks, over the past few months, playing the supporting role. Cisco Systems, Inc.’s (NASDAQ:CSCO) latest report hints at another attack hovering over Ukraine, once again, which might cause a complete blackout in the country.
PFPT FEYE EFX PANW CSCO NTGR
Cybersecurity has become an increasingly important issue that companies have to address as they continue to develop new platforms and mobile apps. Hackers have been able to steal credit card and personal information from major companies like Equifax, JPMorgan and Home Depot. As a result, cybersecurity has become more necessary, and instead of developing a dedicated department within a company, most opt to hire a third-party cybersecurity firm.
CYBR HD FEYE PANW CHKP FTNT
We value the business on a zero-growth earnings power basis, compare the earnings yield to Alphabet's (the Google hurdle) and assess the investment opportunity.
GOOGL PANW FTNT
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to PANW / Palo Alto Networks, Inc. on message board site Silicon Investor.
|Palo Alto Networks, Inc.|
as of ET